Clinical Trial

A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA

Name: A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA — clinical trial record (NCT07738822)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) to evaluate safety and tolerability.

Trial Details

NCT Number	NCT07738822
Lead Sponsor	Cullinan Therapeutics Inc.
Conditions	Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Enrollment	72 participants
Start Date	2026-12
Primary Completion	2029-01 (estimated)
Study Completion	2031-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-31